Application of butylphthalide in preparation of medicament for treating bronchial asthma
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A bronchial asthma and butylphthalide technology, applied in the field of medicine, can solve problems such as arrhythmia, excited heart, adverse reactions, etc.
Inactive Publication Date: 2012-11-28
GANSU UNIV OF CHINESE MEDICINE
View PDF5 Cites 6 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] At present, the chemicals used to treat asthma mainly include glucocorticoids, beta 2 Receptor agonists and xanthines and other drugs, although the curative effect is reliable, but the adverse reactions are relatively large
Glucocorticoids are effective, but they have a wide range of effects, a
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0058] Embodiment 1, the preparation of butylphthalide soft capsule preparation
[0059] Raw material ratio: butylphthalide soft capsules are composed of capsule material and medicinal liquid oil. The medicinal liquid oil is mainly composed of butylphthalide and vegetable oil as a diluent. The weight ratio of the two is 1:1~100. The capsule material is mainly composed of Composed of rubber, plasticizer and water, the weight ratio of the three is 1:0.2~0.4:0.8~1.30.
[0060] The specific preparation process refers to Chinese patent ZL200310119336.1.
Embodiment 2
[0061] The preparation of embodiment 2, butylphthalide dropping pills
[0062] Raw material ratio: butylphthalide dripping pills are composed of active ingredient butylphthalide, matrix, dispersant, and coating materials. The matrix is selected from polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 20000, poloxamer. The dispersant is selected from light micro silica gel and cross-linked povidone. The coating material is selected from hypromellose, hydroxypropyl cellulose, ethyl cellulose, Eudragit E30D.
[0063] The specific preparation process refers to Chinese patent ZL200510136358.8.
Embodiment 3
[0064] Embodiment 3, the preparation of butylphthalide freeze-dried powder injection
[0065] Raw material ratio: The freeze-dried powder injection of butylphthalide is mainly made of butylphthalide, emulsifier and co-emulsifier, excipient and water for injection, and its raw material weight ratio is butylphthalide: emulsifier: co-emulsifier: Excipients: water for injection is equal to 5~8:1~5:0~1:4~10:5~11.
[0066] The preparation process refers to the preparation method of butylphthalide freeze-dried powder injection described in Chinese patent ZL200410012533.8. The preparation method is as follows: weigh the raw materials of each component according to the proportion, first add butylphthalide, emulsifier and co-emulsifier together with part of water for injection and stir at high speed; take another part of water for injection to dissolve the excipient, adding 0.1% of the total weight Activated carbon, decarbonized after heating at 100°C for 15 minutes, mixed the two solu...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides novel medical application of butylphthalide, i.e. the application of the butylphthalide in the preparation of a medicament for treating the bronchial asthma. The experimental research on the spasmolysis of the butylphthalide on the isolated tracheal smooth muscle of a guinea pig and the influence of the butylphthalide on the incubation period of asthma of the guinea pig shows that the butylphthalide in the concentration range of 3.68*10-6 to 3.68*10-4g/mL has obvious spasmolysis on the tracheal smooth muscle of the guinea pig in the isolated spasticity caused by 5*10-6g/mL of acetylcholine or histamine. On the basis of continuously applying the butylphthalide to the guinea pig which is sensitive for the acetylcholine and the histamine for 10 days, a mixture of the acetylcholine and the histamine is atomized and sucked and the incubation period of asthma is observed. A result shows that 30 mg/kg and 90 mg/kg of butylphthalide has an effect of relieving the tracheospasm of the guinea pig, which is caused by the acetylcholine and the histamine. Therefore, the butylphthalide has a treatment effect on the asthma guinea pig and the treatment effect of the butylphthalide on the asthma guinea pig is related to the effect of inhibiting Ca2+ inner flow and expanded tracheal smooth muscle of the butylphthalide.
Description
technical field [0001] The invention belongs to the field of medicine, and relates to the medical use of a compound butylphthalide, in particular to the application of a compound butylphthalide as an active ingredient in the preparation, prevention or treatment of bronchial asthma. Background technique [0002] Bronchial asthma (referred to as asthma) is a chronic airway inflammatory disease involving a variety of inflammatory cells, especially mast cells, eosinophils and T lymphocytes. In susceptible persons, this inflammation can cause recurrent wheezing, Symptoms such as shortness of breath, chest tightness, and cough often occur at night or in the early morning, and the airway is more responsive to various stimuli. The 2006 version of the Global Initiative for Asthma (The Global Initiative for Asthma, GINA) proposed that the global incidence of asthma is 1%-18%, and there are about 300 million asthma patients in the world; the prevalence of asthma in my country is about ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more